Vinge Logotype
SvenskaEnglish 18D7E0DE-2035-40AE-A740-8F45A358A8F4 Login
  1. Home
  2. Mandates
  3. Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab
Mandate

Vinge advises Axcel VI and Currentum in connection with the acquisitions of Gullikssons El, Elkalkyl och Elprojektering and Reglerab

September 13, 2022 Employment and Benefits M&A Banking and Finance Real Estate and Construction

Vinge advises Axcel VI and the Currentum Group in connection with the acquisitions of J. Gullikssons El Aktiebolag, Elkalkyl och Elprojektering i Sverige AB and Reglerab AB.

The companies provide services in planning, installation and service in the electrical and construction sectors and are based in Stockholm and Mälardalen. Together, the companies have a turnover of approximately SEK 155 million and approximately 100 employees. Following the acquisitions, Currentum is expected to have a turnover of approximately SEK 3 billion and will engage just over 1,000 employees.

Vinge’s team consisted of partner Christina Kokko together with Carl Fredrik Wachtmeister, Linnea Petersson and Philip Moré (M&A), Isak Willborg (Construction), Sara Strandberg (Employment), Calle Tengwall Pagels (Financing), Frida Ställborn (Real Estate) and Anna Ekdahl Roos (project assistant).

Related

Vinge advised Precise Biometrics

 Vinge has advised Precise Biometrics AB in connection with the merger with Fingerprint Cards.
March 27, 2026

Vinge has advised Xspray Pharma in connection with its rights issue

Vinge has advised Xspray Pharma AB (publ) in connection with a rights issue of approximately SEK 83 million before transaction costs, with an over-allotment issue of approximately SEK 30 million.
March 26, 2026

Vinge advises Diamyd Medical in connection with directed issuances of shares and warrants of up to SEK 1,166 million

 Vinge advises Diamyd Medical Aktiebolag (“Diamyd Medical”), listed on Nasdaq First North Growth Market, in connection with directed issuances of shares and warrants whereby Diamyd Medical receives gross proceeds of approximately SEK 1,166 million, if all warrants are exercised.
March 25, 2026